

Special Issue

New Approaches in Radiotherapy for Cancer

Message from the Guest Editors

In the dynamic field of radiotherapy, recent years have witnessed groundbreaking advancements reshaping cancer treatment. Progress has been driven by advanced imaging, artificial intelligence, next-generation treatment machines, online adaptive platforms, novel modalities, and a deeper understanding of radiobiology. Key innovations include adaptive therapy, spatially fractionated radiotherapy, FLASH, immuno-radiotherapy, proton and particle therapy, SRS for multiple brain metastases, radiogenomics, HDR brachytherapy, automated planning, advanced dose calculation, and 3D printing. These developments enable more precise, effective, and personalized radiotherapy. This Special Issue aims to highlight and explore these transformative innovations. We cordially invite you to submit cutting-edge research or review articles. Your contributions will help disseminate knowledge and foster further collaboration in the field. We look forward to your submissions and the insightful discussions they will inspire.

Guest Editors

Dr. Dandan Zheng
Dr. Alexander Podgorsak
Dr. Olga Maria Dona Lemus

Deadline for manuscript submissions

closed (30 May 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/192151

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)